A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

Plain-language guide to NCT07073417: phase 2 randomized trial of Semaglutide and Ecnoglutide, 163 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT07073417
Phase: phase 2
Status: active, not recruiting
Start: 2025-07-28
Completion (planned or actual): 2027-02-27
Participants: 163 (actual)
Design: randomized, open label (everyone knows who gets what), treatment
Conditions studied: Obesity; Weight Management
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

This registered phase 2 trial tested Semaglutide and Ecnoglutide.

It had two arms (groups): XW003 (experimental) and semaglutide (active comparator).

Once weekly.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 163 actual participants took part.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: BMI≥30 kg/m2 at screening, waist circumference ≥90 cm for men and ≥85 cm for women.

The full record lists 2 inclusion and 6 exclusion criteria; among the exclusions: diagnosis with any type of diabetes (except gestational diabetes); history of acute or chronic pancreatitis or pancreatic injury, history of symptomatic gallbladder disease (except cholecystectomy).

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Semaglutide group and the comparison group ran side by side rather than switching.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

It started in 2025-07-28 with completion listed for 2027-02-27.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percentage change in body weight relative to baseline (time frame: week 48).

It also tracked 5 secondary outcomes, for example The change in waist circumference relative to the baseline and Changes in body mass index (BMI) relative to baseline.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide and Ecnoglutide in 163 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page and the Ecnoglutide compound page, all human trials.

Our Notes on the Compounds

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Ecnoglutide: A once-weekly cAMP-biased GLP-1 receptor agonist from Sciwind Biosciences, approved in China in 2026 for type 2 diabetes and weight management.

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.